Navigation Links
MicroPhage Selects Lynn Taussig, MD for Board of Directors
Date:12/2/2008

LONGMONT, Colo., Dec. 2 /PRNewswire/ -- MicroPhage, Inc., http://www.microphage.com, announced today that Lynn M. Taussig, MD has joined the company's Board of Directors. Taussig was president and CEO of National Jewish Medical and Research Center in Denver, the nation's leading institution for studying respiratory diseases, from 1993 to 2006. His medical specialty is pediatric pulmonology.

"I have followed MicroPhage extensively and am impressed with its progress in developing new, rapid bacterial identification and antibiotic susceptibility tests, and am enthused about the clinical impact their products will have in providing accurate and cost-effective diagnosis of serious infections," said Taussig.

MicroPhage CEO Steve Lundy knows Taussig's expertise in diagnosis and management of respiratory diseases and his healthcare management experience will be valuable to the board in guiding the company's future. "We are pleased to have a physician and hospital executive of Dr. Taussig's stature join our board. His involvement and support shows confidence in MicroPhage, and his clinical expertise and vision will be deeply valued," said Lundy.

Taussig has served on numerous academic, government and business boards and commissions and has authored more than 170 publications related to respiratory illnesses in children. He has earned several academic, civic and professional honors, including the Distinguished Achievement Award from the American Thoracic Society. He currently serves as special advisor to the Provost for Life Sciences at the University of Denver and is on the Board of Directors of the Colorado Biosciences Association.

MicroPhage is in late stage development for its bacterial detection and susceptibility diagnostic system. The first products are targeted for rapid detection of MRSA (methicillin-resistant Staphylococcus aureus) and MSSA (methicillin-sensitive Staphylococcus aureus) for screening and diagnostic applications.

About MicroPhage

Based in Longmont, Colo. and privately held, MicroPhage, Inc. is working to be a global leader in developing rapid diagnostics products for bacterial identification and antibiotic susceptibility/resistance testing. Using its bacteriophage-based amplification platform for immunoassay diagnostics, the company has developed a patented process that is a product platform or engine for rapid, easy-to-use, inexpensive bacterial identification and antibiotic susceptibility testing. Its first products, expected in late 2009, will set a new standard for clinicians in MRSA identification and antibiotic susceptibility testing, and are designed to fit the demands for improving laboratory workflow. For further information, go to http://www.microphage.com.


'/>"/>
SOURCE MicroPhage
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New Research Shows MicroPhage Test Accurately and Rapidly Detects Serious Bacterial Infections
2. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
3. Purdue Pharma Selects Systech to Provide Sustainable Infrastructure for Serialization
4. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
5. West Penn Allegheny Health System Selects Electronic Health Record From Allscripts
6. ABMS Selects Kevin B. Weiss, MD, MPH, as New President and CEO
7. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
8. Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment
9. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
10. Delhaize Group Selects Trintechs AssureNET GL to Improve Compliance Process Efficiency
11. Financial Times Selects CAMFED International for 2007 Reader Seasonal Appeal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the Root ... Orleans. This is a new, greatly improved version of the Doctor Referral teaming dataset ... by Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released by ...
(Date:6/24/2017)... York (PRWEB) , ... June 24, 2017 , ... ... the Dental365 family. Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers ... evenings and weekends so that visits to the dentist fit into their patients’ ...
(Date:6/23/2017)... ... 23, 2017 , ... By scoring 100% for fiscal management and accountability, the ... online charity evaluator, Charity Navigator, validating ANRF's work as a top charity in America. ... Charity Navigator and earns ANRF a spot on their “ 10 Charities Worth Watching ...
(Date:6/23/2017)... ... 2017 , ... Military Connection friend and veteran advocate Micaela Bensko ... Atlantic lounge. , Bensko is no stranger to the plight of the disabled. ... life to supporting our wounded veterans. A world-class photographer, her riveting photos “The Wounds ...
(Date:6/23/2017)... ... 2017 , ... Georgia State University will host the First ... two-day conference is focused on advancing scientific knowledge about the aggressive triple negative ... racial breast cancer-related disparities. The conference theme is “Illuminating Actionable Biology.” , Conference ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ) today ... R. Goodwin , U.S. District Court Judge for the ... entered a case management order in MDL 2325, American ... (the "MDL") that includes a provision requiring plaintiffs in ... specific causation within one hundred twenty (120) days of ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly and ... that results from the Phase 3 MONARCH 2 ... & 6 inhibitor, in combination with fulvestrant, significantly ... fulvestrant alone in women with hormone-receptor-positive (HR+), human ... cancer who have relapsed or progressed after endocrine ...
Breaking Medicine Technology: